Article
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Leukemia & lymphoma - 1 Jan 2015
Ganjoo Kristen N, de Vos Sven, Pohlman Brad L, Flinn Ian W, Forero-Torres Andres, Enas Nathan H, Cronier Damien M, Dang Nam H, Foon Kenneth A, Carpenter Susan P, Slapak Christopher A, Link Brian K, Smith Mitchell R, Mapara Markus Y, Wooldridge James E
Abstract excerpt
This phase 2 study assessed the safety and efficacy of ocaratuzumab, a humanized anti-CD20 monoclonal antibody. Fifty patients with previously treated follicular lymphoma (FL) and a low-affinity genotype of FcγRIIIa received ocaratuzumab 375 mg/m(2) weekly for 4 weeks. Grade 3/4/5 adverse events (AEs) were reported in 11/1/1 patients, respectively. Serious AEs were reported by 11/50 patients, and three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.